The SPARC trial, sponsored by Hospices Civils de Lyon, aims to evaluate the efficacy of personalized alpha transcranial alternating current stimulation (tACS) in patients with disorders of consciousness following traumatic brain injury. Given the limited therapeutic options currently available for DoC, this study addresses a significant unmet medical need. If successful, the findings could pave the way for novel non-invasive treatment modalities, potentially capturing a share of the neurorehabilitation market, which is increasingly focused on innovative neuromodulation techniques. The trial's design, utilizing a Single-Case Experimental Design (SCED), enhances the sensitivity of results, which may attract interest from pharmaceutical companies and investors looking to expand their portfolios in neuromodulation therapies. However, the small sample size may limit initial commercial viability until further confirmatory studies are conducted.